Did Money Motivate AbbVie's Galapagos Decision?
This article was originally published in Scrip
You may also be interested in...
Clinical data shows Ablynx's anti-IL 6R vobarilizumab (ALX0061) to have efficacy in the same range as Roche's Actemra as a monotherapy for rheumatoid arthritis. With more data due shortly, Ablynx is confident that AbbVie will exercise its option for the product.
News that Belgium's Galapagos and partner Gilead are to advance a higher dose of JAK1 inhibitor filgotinib into Phase III help allay lingering doubts over testicular toxicity with the drug, the rights to which AbbVie had unexpectedly handed back.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.